Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3185-3190

  Johnson, Sara M ^a   Gulhati, Pat ^a,b   Arrieta, Isela ^a   Wang, Xiaofu ^a   Uchida, Tatsuo ^b   Gao, Tianyan ^a,b   Evers, B Mark ^a,b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Akt; Colorectal cancer; Curcumin; mTOR; PHLPP; Raptor; Rictor

Indexed keywords

CURCUMIN; DNA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; NATURAL PRODUCT; POLYPHENOL; PROTEIN KINASE B INHIBITOR;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HCT116; COLORECTAL CARCINOMA; CONTROLLED STUDY; CURCUMA LONGA; DNA CONTENT; DOSE RESPONSE; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PLANT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CURCUMIN; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 68549083507     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sa G and Das T: Anticancer effects of curcumin: cycle of life and death. Cell Div 3: 14, 2008.
2. Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398, 2003. (Pubitemid 36361976)
3. Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269: 199-225, 2008.
4. Wang X, Wang Q, Ives KL and Evers BM: Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res 12: 5346-5355, 2006. (Pubitemid 44497247)
5. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
6. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ and Phillips WA: The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429, 2001. (Pubitemid 32995029)
7. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201-205, 2002. (Pubitemid 34213570)
8. Rychahou PG, Jackson LN, Silva SR, Rajaraman S and Evers BM: Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243: 833-842; discussion 843-1834, 2006. (Pubitemid 44297494)
9. Rychahou PG, Murillo CA and Evers BM: Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 138: 391-397, 2005.
10. Sheng H, Shao J, Townsend CM Jr and Evers BM: Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 52: 1472-1478, 2003. (Pubitemid 37176728)
11. Wang Q, Li N, Wang X, Kim MM and Evers BM: Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin Cancer Res 8: 1940-1947, 2002.
12. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH and Evers BM: Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 105: 20315-20320, 2008.
13. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007.
14. Gao T, Furnari F and Newton AC: PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13-24, 2005. (Pubitemid 40444644)
15. Brognard J, Sierecki E, Gao T and Newton AC: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917-931, 2007. (Pubitemid 46436532)
16. Liu J, Weiss HL, Rychahou P, Jackson LN, Evers BM and Gao T: Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 28: 994-1004, 2009.
17. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol Pharmacol 69: 195-206, 2006. (Pubitemid 43048906)
18. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW and Kwon TK: Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24: 1199-1208, 2003.
19. Beevers CS, Li F, Liu L and Huang S: Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119: 757-764, 2006. (Pubitemid 44051438)
20. Yu S, Shen G, Khor TO, Kim JH and Kong AN: Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase- dependent mechanism. Mol Cancer Ther 7: 2609-2620, 2008.
21. Chauhan DP: Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 8: 1695-1706, 2002. (Pubitemid 34846196)
22. Chen LA, Li J, Silva SR, Jackson LN, Zhou Y, Watanabe H, Ives KL, Hellmich MR and Evers BM: PKD3 is the predominant protein kinase D isoform in mouse exocrine pancreas and promotes hormone-induced amylase secretion. J Biol Chem 284: 2459-2471, 2009.
23. Patel H, Polanco-Echeverry G, Segditsas S, Volikos E, McCart A, Lai C, Guenther T, Zaitoun A, Sieber O, Ilyas M, Northover J and Silver A: Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer 121: 2668-2673, 2007. (Pubitemid 350136410)
24. Reddy S, Rishi AK, Xu H, Levi E, Sarkar FH and Majumdar AP: Mechanisms of curcumin- and EGF receptor-related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr Cancer 55: 185-194, 2006. (Pubitemid 44719633)
25. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D and Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308, 2005. (Pubitemid 40341176)
26. Li M, Zhang Z, Hill DL, Wang H and Zhang R: Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67: 1988-1996, 2007.
27. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB and Kondo Y: Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72: 29-39, 2007. (Pubitemid 46998522)
28. Shinojima N, Yokoyama T, Kondo Y and Kondo S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 3: 635-637, 2007. (Pubitemid 350060068)
29. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ and Huang S: Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res 69: 1000-1008, 2009.
30. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP and Gescher AJ: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14: 120-125, 2005. (Pubitemid 40165291)